McKesson Corporation (NYSE: MCK) is a Healthcare company in the Medical - Distribution industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | S&P 500 | P/E | 23.17 | EPS (ttm) | 37.53 | Insider Own | 0.23% | Shs Outstand | 117.08M | Perf Week | 1.56% |
| Market Cap | 101.81B | Forward P/E | 17.24 | EPS next Y | 50.45 | Insider Trans | -12.77% | Shs Float | 120.01M | Perf Month | 9.68% |
| Enterprise Value | 108.35B | PEG | 0.47 | EPS next Q | - | Inst Own | 88.27% | Short Float | 3.23% | Perf Quarter | 15.21% |
| Income | 4.53B | P/S | 0.25 | EPS this Y | 15.64% | Inst Trans | - | Short Ratio | 3.36 | Perf Half Y | -9.21% |
| Sales | 411.02B | P/B | - | EPS next Y | 13.39% | ROA | 5.20% | Short Interest | 3.88M | Perf YTD | 6.01% |
| Book/sh | - | P/C | 15.06 | EPS next 5Y | 15.92% | ROE | -194.39% | 52W High | 1013.30 -12.95% | Perf Year | 23.56% |
| Cash/sh | - | P/FCF | 15.35 | EPS past 3/5Y | 15.30% - | ROIC | 27.91% | 52W Low | 646.17 36.51% | Perf 3Y | 110.52% |
| Dividend Est. | 3.76 (0.43%) | EV/EBITDA | 15.16 | Sales past 3/5Y | 13.39% 11.11% | Gross Margin | 3.64% | Volatility | 4.73% 2.97% | Perf 5Y | 326.62% |
| Dividend TTM | 3.28 (0.37%) | EV/Sales | 0.26 | EPS Y/Y TTM | 49.57% | Oper. Margin | 1.62% | ATR (14) | 28.84 | Perf 10Y | 349.53% |
| Dividend Ex-Date | Sep 01, 2026 | Quick Ratio | 0.52 | Sales Y/Y TTM | 12.36% | Profit Margin | 1.12% | RSI (14) | 59.58 | Recom | 2.16 |
| Dividend Gr. 3/5Y | 14.85% 13.01% | Current Ratio | 0.89 | EPS Q/Q | 45.58% | SMA20 | 3.15% | Beta | 0.31 | Target Price | 1007.50 |
| Payout | 8.56% | Debt/Eq | - | Sales Q/Q | 6.02% | SMA50 | 8.75% | Rel Volume | 1.27 | Prev Close | 869.58 |
| Employees | 43,000 | LT Debt/Eq | -8.47 | Earnings | Nov 04 | SMA200 | 3.81% | Avg Volume | 1.17M | Price | 882.08 |
| IPO Date | Nov 10, 1994 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 1.08% -4.98% | Net Debt/EBITDA | 0.91 | Volume | 1,486,282 | Change | 1.44% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-06-26 | Reiterated | Robert W. Baird | $955 → $1015 | |
| May-08-26 | Reiterated | Deutsche Bank | Buy | $973 → $875 |
| May-08-26 | Reiterated | UBS | Buy | $920 → $1050 |
| Mar-05-26 | Reiterated | Raymond James | Market Perform | $970 |
| Mar-05-26 | Reiterated | Leerink Partners | Outperform | $665 → $1085 |
| Feb-18-26 | Reiterated | Barclays | Overweight | $960 → $1050 |
| Jan-29-26 | Reiterated | Morgan Stanley | Overweight | $916 → $966 |
| Jan-14-26 | Reiterated | Robert W. Baird | $928 → $968 | |
| Dec-08-25 | Initiated | Barclays | Overweight | $290 → $960 |
| Nov-06-25 | Reiterated | Evercore ISI | Outperform | $825 → $1000 |
McKesson Corporation is a prominent global provider of healthcare services, operating extensively in both the United States and international markets. Its diverse operations are strategically organized into four key business segments. The U.S. Pharmaceutical division plays a crucial role in the distribution of a comprehensive array of pharmaceutical products, encompassing branded, generic, specialty, biosimilar, and over-the-counter medications, alongside other health-related merchandise. This segment also delivers specialized support to community-based oncology and other specialty medical practices through practice management tools, technology solutions, clinical guidance, and broader business services. Furthermore, it assists pharmacies with consulting, outsourcing, and technology services, while also furnishing financial, operational, and clinical software solutions. Internationally, the company's dedicated segment provides distribution and support services to wholesale, institutional, and retail clients across 13 European nations and Canada. The Medical-Surgical Solutions unit is focused on supplying healthcare providers with essential medical-surgical products, sophisticated logistics management, and a variety of associated services. Finally, the Prescription Technology Solutions (RxTS) segment is designed to address complex medication challenges for patients. It collaborates with biopharmaceutical companies and life sciences partners to improve patient journeys, leveraging innovative solutions for medication access and adherence by connecting pharmacies, healthcare providers, payers, and biopharma entities. This segment further offers third-party logistics and wholesale distribution assistance. Founded in 1833, McKesson Corporation maintains its corporate headquarters in Irving, Texas.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2026 3/31/2026 | FY 2025 3/31/2025 | FY 2024 3/31/2024 | FY 2023 3/31/2023 | FY 2022 3/31/2022 | FY 2021 3/31/2021 | FY 2020 3/31/2020 | FY 2019 3/31/2019 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 410,983 | 403,430 | 359,051 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 396,027 | 388,880 | 346,566 | — | — | — | — | — | — | |
| Gross Profit | 14,956 | 14,550 | 12,485 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 4,104 | -8,096 | 8,022 | — | — | — | — | — | — | |
| Research and Development | 0 | 103 | 91 | — | — | — | — | — | — | |
| Other Operating Expense | 4,198 | 16,089 | 0 | — | — | — | — | — | — | |
| Operating Income | 6,654 | 6,454 | 4,372 | — | — | — | — | — | — | |
| Interest Expense | 153 | 247 | 256 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -43 | -6 | 243 | — | — | — | — | — | — | |
| Net Income Before Taxes | 6,458 | 6,201 | 4,359 | — | — | — | — | — | — | |
| Income Taxes | 1,158 | 1,102 | 878 | — | — | — | — | — | — | |
| Consolidated Net Income | 4,592 | 4,762 | 3,295 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 5,300 | 5,099 | 3,481 | — | — | — | — | — | — | |
| Net Income | 4,592 | 4,762 | 3,295 | — | — | — | — | — | — | |
| EPS (Recurring) | 37.53 | 38.55 | 25.86 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 37.53 | 38.55 | 25.86 | — | — | — | — | — | — | |
| EPS (Diluted) | 37.37 | 38.38 | 25.72 | — | — | — | — | — | — | |
| EBITDA | 7,145 | 7,177 | 5,251 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 23.60 | 22.55 | 26.17 | — | — | — | — | — | — | |
| Price To Sales Ratio | 0.26 | 0.27 | 0.24 | — | — | — | — | — | — | |
| Gross Margin | 3.64 | 3.61 | 3.48 | — | — | — | — | — | — | |
| Operating Margin | 1.62 | 1.60 | 1.22 | — | — | — | — | — | — | |
| Net Margin | 1.12 | 1.18 | 0.92 | — | — | — | — | — | — | |
| Shares Outstanding | 119 | 124 | 127 | — | — | — | — | — | — | |
| Market Capitalization | 104,968 | 107,305 | 85,470 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| TYLER BRIAN S. | Chief Executive Officer | Jul 07 '26 | Sale | 793.56 | 8,463 | 6,715,898 | 5,919 | Jul 08 |
| TYLER BRIAN S. | Chief Executive Officer | Jun 17 '26 | Sale | 775.13 | 8,463 | 6,559,925 | 14,382 | Jun 18 |
| TYLER BRIAN S. | Chief Executive Officer | Jun 09 '26 | Sale | 763.00 | 4,929 | 3,760,827 | 22,845 | Jun 11 |
| Rutledge Napoleon B JR | SVP, Controller & CAO | Jun 05 '26 | Sale | 764.00 | 133 | 101,612 | 632 | Jun 08 |
| Rodgers Thomas L | EVP, Chief Strategy & BDO | Jun 02 '26 | Sale | 735.27 | 699 | 513,954 | 2,268 | Jun 03 |
| Rodgers Thomas L | EVP, Chief Strategy & BDO | Jun 01 '26 | Sale | 735.50 | 123 | 90,467 | 2,967 | Jun 03 |
| Smith LeAnn B | EVP & Chief HR Officer | Jun 01 '26 | Sale | 735.50 | 1,810 | 1,331,255 | 4,798 | Jun 02 |
| Rodgers Thomas L | EVP, Chief Strategy & BDO | May 26 '26 | Sale | 761.09 | 2,388 | 1,817,483 | 3,090 | May 27 |
| Lau Michele | EVP and Chief Legal Officer | May 26 '26 | Sale | 761.09 | 3,550 | 2,701,870 | 3,247 | May 27 |
| Vitalone Britt J. | EVP & CFO | May 23 '26 | Option Exercise | 0.00 | 1,476 | 0 | 22,534 | May 27 |
| Smith LeAnn B | EVP & Chief HR Officer | May 23 '26 | Option Exercise | 0.00 | 679 | 0 | 6,876 | May 27 |
| Rodgers Thomas L | EVP, Chief Strategy & BDO | May 23 '26 | Option Exercise | 0.00 | 594 | 0 | 5,712 | May 27 |
| TYLER BRIAN S. | Chief Executive Officer | May 23 '26 | Option Exercise | 0.00 | 4,579 | 0 | 29,605 | May 27 |
| Rutledge Napoleon B JR | SVP, Controller & CAO | May 23 '26 | Option Exercise | 0.00 | 136 | 0 | 806 | May 27 |
| Fraga Francisco | EVP, CIO and CTO | May 23 '26 | Option Exercise | 0.00 | 136 | 0 | 6,264 | May 27 |